Please click below to access the 2020 Autonomic Disorders reading list.
The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content.
The American Academy of Neurology Institute designates this enduring material for a maximum of 11 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To claim CME credits, answer question 26 on the quiz to reflect the total time spent completing the required reading and online quiz. This question is not included in the scoring of the quiz. A passing score of 80% of higher is needed to meet C-cert requirements and receive CME credit. CME credit confirmation will be emailed within ten business days of passing the quiz.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Neurology Institute (AANI) and United Council for Neurologic Subspecialties. The AANI is accredited by the ACCME to provide continuing medical education for physicians.
The UCNS complies with all standards and policies of the ACCME, including identiﬁcation and resolution of all conﬂicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS planners, authors, and staff comply with the UCNS’s Conﬂicts of Interest Policy.
Paola Sandroni, MD, PhD, Mayo Clinic - Rochester
Disclosures: Nothing to disclose.
William P. Cheshire, MD, Mayo Clinic - Jacksonville
Disclosures: Received reimbursement from Wolters Kluwer for writing for UpToDate; Received research support in the form of travel reimbursement from Biohaven to attend research investigators’ meeting.
Elizabeth Coon, MD, Mayo Clinic – Rochester
Disclosures: Nothing to disclose.
Roy L. Freeman, MD, Beth Israel Deaconess Hospital
Disclosures: Received personal compensation and/or stock options for serving on scientific advisory boards of: Abide, Applied Therapeutics, Astellas, Aptinyx, Biogen, Biohaven, Cutaneous NeuroDiagnostics, GW Pharma, Ironwood, Lundbeck, MundiPharma, NeuroBo, Novartis, Pfizer, Regenacy, Spinifex, Toray, Theravance and Vertex; Holds stock or stock options for NeuroBo as chair of the scientific advisory board; Received research support from Biogen for quality control of skin biopsy data, from Theravance for trials and study for orthostatic hypotension trial. Received research support from Biohaven for trial of multiple system atrophy.
David S. Goldstein, MD, PhD, NINDS, NIH
Disclosures: Received research funding from the United States government.
Phillip A. Low, MD, FAAN, Mayo Clinic – Rochester
Disclosures: Received personal compensation from WR Medical for consultant services.
Peter Novak, MD, PhD, Brigham and Women's Faulkner Hospital
Disclosures: Received personal compensation as Advisor - independent contractor for Dysimmune Diseases Foundation. Member of Scientific Advisory Board for Endonovo Therapeutics. Received royalties for authored book, Autonomic Testing; Holds stock in Pfizer.
Brian Olshansky, MD, University of Iowa Hospitals and Clinics
Disclosures: Received personal compensation from Boehringer Ingelheim, Lundbeck, Amarin, Sanofi-Aventis, and Respironics for consultant services.
Lauren Phillips, MD, UT Southwestern Medical School
Disclosures: Received personal compensation as a consultant for ACI Clinical - Neurology Endpoint Adjudication Committee; Received research support from NeuroNEXT (Network for Excellence in Neuroscience Clinical Trials) funded by National Institute of Health’s National Institute of Neurological Disorders and Stroke (NINDS) for project: Topirimate as a Disease Altering Therapy for role as for Cryptogenic Sensory Peripheral Neuropathy (CSPN) [NN108 TopCSPN], role as site principal investigator; Received research support from Grifols Pharmaceuticals (Industry) for project: Dysautonomia International Title of Project: iSTAND: IVIG (Gamunex-C) Study of Treatment for Autoimmune Neuropathic Dysautonomia/Postural Tachycardia (POTS), Role: Co-Investigator.
Bryan Hagerla, Continuous Certification Manager